Anika Therapeutics (ANIK) to Release Earnings on Tuesday

Anika Therapeutics (NASDAQ:ANIK) will be releasing its earnings data after the market closes on Tuesday, February 13th. Analysts expect Anika Therapeutics to post earnings of $0.46 per share for the quarter.

Shares of Anika Therapeutics (ANIK) opened at $62.36 on Tuesday. Anika Therapeutics has a 1 year low of $41.64 and a 1 year high of $69.81. The firm has a market capitalization of $947.15, a PE ratio of 29.28, a P/E/G ratio of 3.92 and a beta of 1.60.

In other Anika Therapeutics news, insider Richard Hague sold 5,250 shares of Anika Therapeutics stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $54.48, for a total transaction of $286,020.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.57% of the stock is currently owned by insiders.

A number of research firms have weighed in on ANIK. Barrington Research reaffirmed a “buy” rating and set a $57.00 price objective on shares of Anika Therapeutics in a report on Thursday, December 28th. BidaskClub raised Anika Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Sidoti began coverage on Anika Therapeutics in a report on Friday, January 26th. They set a “buy” rating on the stock. Finally, First Analysis raised Anika Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $45.00 to $68.00 in a report on Wednesday, January 24th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $62.50.

ILLEGAL ACTIVITY WARNING: “Anika Therapeutics (ANIK) to Release Earnings on Tuesday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Earnings History for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply